Mangano C, Squadrito G, Cacciola I, Carpentieri M, Foti G, Raimondo G

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 84-87
Archivo PDF: 161.36 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ganem D, Prince AM. Hepatitis B virus infection- natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.

2. Lok AS, MacMahon BJ. Chronc Hepatitis B. Hepatology 2007; 45: 507-39.

3. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.

4. Mutimer D, Naoumov NV, Honkoop P, Marinos G, Ahmed M, de Man R, McPhillips P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitits B infection: results of a pilot study. J Hepatol 1998; 28: 923-9.

5. Serfaty L, Thabut D, Zoulim F, Andreani T, Chazoulliers O, Carbonell N, Loria A, Poupon R. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of pilot study. Hepatology 2001; 34: 573-7.

6. 6 Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha- interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35: 805-10.

7. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36: 799-804.

8. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.

9. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positve chronic hepatitis B: a randomized controlled trial. Lancet 2005; 365: 123-9.

10. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, et al. Peginterferon Alfa-2a HBe- Ag-Positive Chronic Hepatitis B Study Group. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.

11. Yurdaydin C, Bozkaya H, Cetinkaya H,et al. Lamivudine vs lamivudine and interferon combination treatment of HBeAg(-) chronic hepatitis B. J Viral Hepat 2005; 12: 262-8.

12. Manesis EK, Papatheodoridis GV, Hadziyannis SJ. A partially overlapping treatment course with lamivudine and interferon in hepatitis Be antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2006; 23: 99-106.

13. Kumar M, Sarin K. Systematic review: combination therapies for treatment-naïve chronic hepatitis B. Aliment Pharmacol Ther 2008; 27: 1187-209.

14. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 5: 431-5.

15. Caroleo B, Gallelli L, Staltari O, De Sarro G, Guadagnino V. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol. Intervirology 2008; 51(6): 407-9.

16. Basso M, Giannini EG, Torre F, Blanchi S, Savarino V, Picciotto A. Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNAnegative patients are associated with virological relapse. Hepatology 2009; 49(5): 1442-8.

17. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.

18. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, et al. Lamivudine treatment can restore T cell responsiveness inn chronic hepatitis B. J Clin Invest 1998; 102: 968-875.